Wei Li

Research Associate Professor

  • 959 Citations
1991 …2023
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Wei Li is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Phagocytosis Medicine & Life Sciences
Bacteriophages Medicine & Life Sciences
Ligands Medicine & Life Sciences
Proteins Medicine & Life Sciences
Open Reading Frames Medicine & Life Sciences
Epithelial Cells Medicine & Life Sciences
Neuropeptide Y Medicine & Life Sciences
Angiogenesis Inducing Agents Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2001 2023

Retinopathy of Prematurity
Vascular Endothelial Growth Factor A
Angiogenesis Inducing Agents
Anti-Idiotypic Antibodies
Neutralizing Antibodies
Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Macular Edema
Angiogenesis Inducing Agents
Pathologic Neovascularization
Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Antibodies, Monoclonal, Humanized
Therapeutics
Ligands
Retinal Diseases
Angiogenesis Inducing Agents
Ligands
Neutralizing Antibodies
Vascular Endothelial Growth Factor A
Microglia
Phagocytes
Molecular Biology
Phagocytosis
Ligands

Research Output 1991 2019

Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety

Tang, F., LeBlanc, M. E., Wang, W., Liang, D., Chen, P., Chou, T. H., Tian, H. & Li, W., Jan 1 2019, (Accepted/In press) In : Angiogenesis.

Research output: Contribution to journalArticle

Retinopathy of Prematurity
Monoclonal Antibodies
Oxygen
Safety
Pathologic Neovascularization

Function-first ligandomics for ocular vascular research and drug target discovery

Rong, X., Tian, H., Yang, L. & Li, W., May 1 2019, In : Experimental Eye Research. 182, p. 57-64 8 p.

Research output: Contribution to journalShort survey

Drug Discovery
Blood Vessels
Research
Ligands
Vascular Endothelial Growth Factor A

Secretogranin III as a novel target for the therapy of choroidal neovascularization

LeBlanc, M. E., Wang, W., Ji, Y., Tian, H., Liu, D., Zhang, X. & Li, W., Apr 1 2019, In : Experimental Eye Research. 181, p. 120-126 7 p.

Research output: Contribution to journalArticle

Choroidal Neovascularization
Monoclonal Antibodies
Neutralizing Antibodies
Vascular Endothelial Growth Factor A
Macular Degeneration
5 Citations (Scopus)

Ligandomics: a paradigm shift in biological drug discovery

Li, W., Pang, I. H., Pacheco, M. T. F. & Tian, H., Mar 1 2018, In : Drug Discovery Today. 23, 3, p. 636-643 8 p.

Research output: Contribution to journalReview article

Drug Discovery
Biological Products
Ligands
Molecular Probes
Therapeutic Uses
3 Citations (Scopus)

Secretogranin III: a diabetic retinopathy-selective angiogenic factor

Li, W., Webster, K. A., LeBlanc, M. E. & Tian, H., Feb 1 2018, In : Cellular and Molecular Life Sciences. 75, 4, p. 635-647 13 p.

Research output: Contribution to journalReview article

Angiogenesis Inducing Agents
Diabetic Retinopathy
Secretory Vesicles
Pathologic Neovascularization
Retinal Neovascularization